Tudor Investment Corp ET AL Makes New Investment in Nurix Therapeutics, Inc. $NRIX

Tudor Investment Corp ET AL purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 37,943 shares of the company’s stock, valued at approximately $351,000.

Other large investors also recently bought and sold shares of the company. Vestal Point Capital LP raised its stake in shares of Nurix Therapeutics by 73.8% in the 3rd quarter. Vestal Point Capital LP now owns 3,475,000 shares of the company’s stock valued at $32,109,000 after acquiring an additional 1,475,000 shares during the period. Perceptive Advisors LLC raised its stake in shares of Nurix Therapeutics by 268.7% in the 2nd quarter. Perceptive Advisors LLC now owns 1,096,985 shares of the company’s stock valued at $12,495,000 after acquiring an additional 799,432 shares during the period. Millennium Management LLC raised its stake in shares of Nurix Therapeutics by 64.3% in the 3rd quarter. Millennium Management LLC now owns 1,523,959 shares of the company’s stock valued at $14,081,000 after acquiring an additional 596,401 shares during the period. Algert Global LLC raised its stake in shares of Nurix Therapeutics by 392.4% in the 3rd quarter. Algert Global LLC now owns 563,837 shares of the company’s stock valued at $5,210,000 after acquiring an additional 449,338 shares during the period. Finally, Qube Research & Technologies Ltd raised its stake in shares of Nurix Therapeutics by 100.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 716,535 shares of the company’s stock valued at $6,621,000 after acquiring an additional 359,793 shares during the period.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,661 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $60,772.60. Following the completion of the transaction, the chief financial officer directly owned 45,427 shares of the company’s stock, valued at $754,088.20. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gwenn Hansen sold 4,895 shares of the business’s stock in a transaction dated Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $81,257.00. Following the transaction, the insider directly owned 83,672 shares of the company’s stock, valued at $1,388,955.20. The trade was a 5.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 6.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of Nurix Therapeutics in a research note on Friday, April 10th. Morgan Stanley set a $36.00 price target on shares of Nurix Therapeutics and gave the company an “overweight” rating in a report on Thursday, January 8th. Wells Fargo & Company lowered their price target on shares of Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a report on Thursday, April 9th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of Nurix Therapeutics in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.46.

Nurix Therapeutics Stock Performance

NASDAQ NRIX opened at $16.69 on Friday. Nurix Therapeutics, Inc. has a one year low of $8.19 and a one year high of $22.50. The company has a 50-day simple moving average of $15.68 and a 200-day simple moving average of $15.50. The firm has a market capitalization of $1.73 billion, a PE ratio of -5.28 and a beta of 1.97.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). Nurix Therapeutics had a negative net margin of 411.37% and a negative return on equity of 64.21%. The business had revenue of $6.25 million during the quarter, compared to analyst estimates of $14.25 million. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.